Testing FH-006 injection in patients with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in patients with advanced malignant solid tumors. It aims to determine the maximum tolerated dose (MTD) and the recommended dose for phase II trials (RP2D), as well as to assess preliminary efficacy. Participants will receive FH-006 and be monitored for their response and any adverse effects. The study focuses on individuals who have experienced disease progression after standard treatments or do not have suitable treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Women aged 18 to 75 (inclusive)
2. Subjects with histologically or cytologically confirmed recurrent or metastatic solid tumors who experience disease progression after standard treatment, or who do not have a standard treatment plan or are not suitable for standard treatment.
3. ECOG score is 0 or 1
4. An expected survival of ≥3 months
5. At least one target lesion according to RECIST v1.1 criteria
6. Has a good level of organ function
7. Patients voluntarily joined the study and signed informed consent

Exclusion Criteria:

1. Have other malignancies within the past 5 years
2. Active central nervous system metastasis without surgery or radiotherapy
3. Presence with uncontrollable third space effusion
4. Have undergone other anti-tumor treatment within 4 weeks before the first dose
5. Has severe infection within 4 weeks before the first medication
6. Any active autoimmune disease or a history of autoimmune disease
7. A history of immune deficiency
8. Has serious cardiovascular and cerebrovascular diseases
9. Clinically significant history of lung disease
10. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade I
11. Having undergone surgery on important organs within 4 weeks prior to the first use of medication
12. Used attenuated live vaccine within 28 days prior to the first use of the investigational drug
13. Presence of other serious physical or mental diseases or laboratory abnormalities

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xiaoxue Pi
• Email: Xiaoxue.pi@hengrui.com
• Phone: 0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized neoantigen-pulsed dendritic cell injections for malignant solid tumors

  This study tests personalized dendritic cell injections, with or without immune checkpoint inhibitors, to see if they are safe and can help patients with advanced solid tumors.

  Recruiting ZSky Biotech Inc · Qinhuangdao, Hebei · NCT07752953

• FH-006 injection study for advanced solid tumors

  This study tests FH-006, alone and with SHR-1316 and paclitaxel, to see if it is safe and tolerable in adults with unresectable or metastatic solid tumors who have measurable disease.

  Recruiting at 2 sites Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07136142

• IntraTumor T-Cell Boost with Dual Immune Checkpoint Inhibitors in ARID1A-Mutated Esophageal/Gastric Adenocarcinoma

  A first-in-human test of a single-dose combination of tremelimumab and durvalumab in adults with ARID1A-mutated, non-metastatic esophageal, GEJ, or stomach adenocarcinoma to see if it can increase tumor T cells.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT06824363

• Testing a new treatment for advanced solid tumors

  This study is testing a new treatment called tolododekin alfa for people with advanced solid tumors that haven't improved with standard therapies to see how safe it is and how well it works.

  Recruiting at 5 sites Phase 1 Ankyra Therapeutics, Inc · Bethesda, Maryland and 4 other locations · NCT06171750

• Combining cyclophosphamide, sorafenib, bevacizumab, and atezolizumab for children and young adults with relapsed solid tumors

  This will test whether giving atezolizumab and bevacizumab every three weeks together with daily cyclophosphamide and dose‑adjusted sorafenib is safe and can shrink relapsed or hard‑to‑treat solid tumors in children and young adults, including fibrolamellar carcinoma.

  Recruiting Phase 1/2 St. Jude Children's Research Hospital · Germantown, Tennessee and 1 other locations · NCT05468359

• Testing a new immune therapy for advanced solid tumors resistant to standard treatments

  This study is testing a new immune therapy that uses special cells from patients' tumors to see if it can help people with advanced solid tumors that haven't responded to standard treatments.

  Recruiting Early Phase 1 Vall d'Hebron Institute of Oncology · Barcelona · NCT05141474

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.